Clinical Factors Related to Recurrence of Anterior Segment Neovascularization After Treatment Including Intravitreal Bevacizumab

Angiogenic and Inflammatory Vitreous Biomarkers Associated With Increasing Levels of Retinal Ischemia

“…18,19 There have been numerous recent studies on the efficacy of bevacizumab in controlling the complications of NVG, however these focus on the clinical outcomes or levels of VEGF alone rather than delineating complete vitreous protein profiles. [20][21][22] Many of the studies delineating specific proteins in severe ischemic eye diseases, and specifically NVG, only assessed levels in human aqueous samples 23,24 or were performed in nonhuman models. 25 This study demonstrated trends in a number of proteins, however the following discussion will focus on some of the most notable findings.…”

Clinical Outcomes and Changes in Aqueous Vascular Endothelial Growth Factor Levels After Intravitreal Bevacizumab for Iris Neovascularization and Neovascular Glaucoma: A Retrospective Two-Dose Comparative Study

“…recent study showed that recurrence of anterior segment neovascularization frequently occurs in advanced cases even with 1.25-mg of IVB and trabeculectomy after bevacizumab injection as the primary inhibitory factors for recurrence, 40 we believe that a decreased dose of 0.1 mg bevacizumab via intravitreal injection is at least sufficient as a surgical adjunctive treatment in eyes with advanced NVG, because it can stabilize neovascular activities preoperatively with minimal concerns about complications. In addition, although the interval between repeated injections is likely shorter with the 0.1-mg dose compared with the 1.0-mg dose, administering the lower dose of IVB initially might be recommended to confirm its clinical and biologic effects against both active neovascularization and ischemic retina, especially in highrisk patients.…”

Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma

“…Intraocular injection of bevacizumab may improve the surgical outcome of filtration surgery in neovascular glaucoma [6,7]. However, multiple injections are sometimes necessary because recurrence of anterior segment neovascularization is frequently encountered [4,8,9]. Several studies have reported the safety profile of intravitreal injections of bevacizumab in patients with various retinal pathologies including exudative age-related macular degeneration, central retinal vein occlusion, proliferative diabetic retinopathy, and macular edema, which are associated with upregulation of VEGF production [10][11][12].…”